TNFSF10 and neoplasm: The authors demonstrated that CAR T cells, upon expressing TRAIL, engaged antigen-positive tumor cells, which, furthermore, allowed them to eliminate antigen-negative tumor cells that were sensitized to TRAIL-mediated cell death by low-dose radiotherapy [62].